Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

Geert R. D'Haens, William J. Sandborn, Edward V. Loftus, Stephen B. Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julián Panés, Filip Baert, Jean Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Qian Zhou, Venkata S. Goteti, Nael M. Mostafa, Thao T. Doan, Joel Petersson, Tricia Finney-Hayward, Alexandra P. SongAnne M. Robinson, Silvio Danese

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background & Aims: Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately to severely active CD. Methods: In this phase 3, randomized, double-blind, multicenter trial, eligible adults (Crohn's Disease Activity Index score of 220–450, endoscopic evidence of mucosal inflammation, and previous failure of standard therapies) were randomized to higher induction regimen (adalimumab 160 mg at weeks 0, 1, 2, and 3; n = 308) or standard induction regimen (adalimumab 160 mg at week 0 and 80 mg at week 2; n = 206) followed by 40 mg every other week from week 4 onward. Co-primary end points included clinical remission at week 4 and endoscopic response at week 12. At week 12, patients were re-randomized to maintenance therapy optimized by Crohn's Disease Activity Index and C-reactive protein (CA; n = 92) or serum adalimumab concentrations and/or clinical criteria (TDM; n = 92); exploratory end points were evaluated at week 56. Results: Similar proportions of patients receiving higher induction regimen and standard induction regimen achieved clinical remission at week 4 (44% in both; P = .939) and endoscopic response at week 12 (43% vs 39%, respectively, P = .462). Week 56 efficacy was similar between CA and TDM. Safety profiles were comparable between dosing regimens. Conclusions: Higher induction regimen was not superior to standard induction regimen, and CA and TDM maintenance strategies were similarly efficacious. Adalimumab therapy was well tolerated, and no new safety concerns were identified. (ClinicalTrials.gov, Number: NCT02065570).

Original languageEnglish
Pages (from-to)1876-1890
Number of pages15
JournalGastroenterology
Volume162
Issue number7
DOIs
StatePublished - Jun 2022

Keywords

  • Biologic Agent
  • Inflammatory Bowel Disease
  • Monoclonal Antibody
  • TNF Inhibitor

Fingerprint

Dive into the research topics of 'Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results'. Together they form a unique fingerprint.

Cite this